Q32 Bio Inc. (QTTB) Q2 2026 Earnings Call

Concluded Jul 13, 2026

Jul 13, 2026 0 turns

Period: FY2026 Q2
Runtime: —
Sources: 3 artifacts

8-K 8-K 10-Q

Executive readout · one minute

What matters this quarter

Q32 Bio reported positive 36-week Part B SIGNAL-AA topline results for bempikibart in alopecia areata and plans to initiate a registration-directed program in 1H 2027; the company also completed a $200 million public offering, extending cash runway through Phase 3 topline results.

Signal AA Part B 36-week results 44 Unmet need vs. JAK inhibitors 35 Bempicabart/Benpicabart safety profile 14 Commercial opportunity and market size 12 Durability and remittive effect 10 Registration/Phase 3 plans 10

Management tone

Confident

Net tone +88 · low hedging

Grounding quotes

“we are thrilled to be sharing positive 36-week top-line results from Part B of our Signal AA Phase 2A clinical trial”
“We believe this is a profound result for a biologic with only 36 weeks of treatment, and combined with its well-tolerated safety profile, physicians then pick apart as a potential leading treatment option in alopecia areata”
“Collectively, we believe the Signal AA program represents a foundation for a compelling, multi-billion-dollar Bempickabart franchise in Alfeisha-Ariata and beyond”
“If these results bear out the way we're hoping in a Phase III trial, this should be the first-line treatment for patients with alopecia areata”

Research coverage

3 live sources

Open each available source without leaving this research workspace.

Diluted EPS -$0.44

Net income -$8.95M

Research materials

Open the source you need; every reader stays inside this workspace.

8-K earnings release Filed Aug 5, 2026 8-K call announcement Filed Jul 13, 2026 10-Q report Filed Aug 5, 2026

Key takeaways

What improved, and what deserves a closer read.

↑ Constructive signals

Bempikibart achieved a 35.3% mean SALT reduction and 40% SALT-20 response at Week 36 in Part B, with a well-tolerated safety profile.
Company plans to initiate a registration-directed Phase 3 program in severe/very severe AA in 1H 2027.
Completed $200 million public offering, extending cash runway through Phase 3 topline results.
Part B OLE enrollment ongoing, with potential for monthly/bi-monthly/quarterly maintenance dosing.
R&D expenses declined to $4.3M from $5.2M YoY, reflecting lower ADX-097 spend.

↓ Risks & pressure points

G&A expenses rose to $4.9M from $4.0M YoY on higher stock-based compensation.
Company reported a Q2 net loss of $8.9M ($0.44/share).

Key moments

Read the management remarks selected from the transcript.

“We believe the efficacy, durability, and safety results from Part B have the potential to set the bar for biologics in the treatment of alopecia areata and address the shortcomings of JAK inhibitors. On the pre-specified MITT primary analysis, we saw a clinically meaningful 35.3% mean reduction in score on the severity of alopecia tool, or SALT, over the 36-week treatment period, and Mbempicabart demonstrated promising results with 40% of patients showing robust hair regrowth on the pre-specified SALT20 endpoint.” Speaker 2

“We plan to share the full results from Part B at a future medical meeting. Taken together, we believe this data supports advancement into a registration-directed program, which we intend to initiate in the first half of 2027 following planned regulatory discussions.” Speaker 2

Read transcripts like this one from Claude, ChatGPT or your own code with the earnings call transcript API →